Erasca | Investor Presentation Deck | 41 slides

Slide schematic 6/6

chart 1/1 list 3/3 source-note 1/1 title 1/1

Components 6

line bullet bullet bullet source-note headline

Tools 1

Problem Statement Canvas slide · 70%

list/bullet: Standard-of-Care: Encorafenib + cetuximab (EC) has improved SOC but prognosis is poor; durability limited by resistance; triplet of binimetinib + EC only marginally improved efficacy

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 0

∅

No frameworks

No framework match is anchored to this slide.

Find anything

The chart is a Kaplan-Meier survival curve comparing a control arm to an experimental arm (EC).